A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Postprandial Lipoprotein Response in Patients With Primary Hypercholesterolemia
Latest Information Update: 05 May 2022
At a glance
- Drugs Ezetimibe (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 14 May 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
- 20 Dec 2006 Status change
- 30 Aug 2005 New trial record.